Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting

BACKGROUND: Warfarin, an inexpensive drug that has been available for over half a century, has been the mainstay of anticoagulant therapy for stroke prevention in patients with atrial fibrillation (AF). Recently, rivaroxaban, a novel oral anticoagulant (NOAC) which offers some distinct advantages ov...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleintjens, Joris, Li, Xiao, Simoens, Steven, Thijs, Vincent, Goethals, Marnix, Rietzschel, Ernst R., Asukai, Yumi, Saka, Ömer, Evers, Thomas, Faes, Petra, Vansieleghem, Stefaan, De Ruyck, Mimi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2013
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824571/
https://www.ncbi.nlm.nih.gov/pubmed/24030788
http://dx.doi.org/10.1007/s40273-013-0087-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3824571/
https://www.ncbi.nlm.nih.gov/pubmed/24030788
http://dx.doi.org/10.1007/s40273-013-0087-9

Ejemplares similares